New Haven, Conn. -- Yale University and the National Foundation for Cancer Research (NFCR) announced the establishment of an NFCR Center for Anti-Cancer Drug Design and Discovery to develop new beta-peptide inhibitors that will play critical roles in the fight against many types of cancer.
Funded by a five-year, $750,000 grant from the NFCR, the center will be led jointly by Alanna Schepartz, the Milton Harris, '29 Ph.D. Professor of Chemistry, and William Jorgensen, the Whitehead Professor of Chemistry at Yale.
"We are delighted that the NFCR has chosen to support Yale as a place where cutting-edge drug discovery research in chemistry is making, and will continue to make, an impact in the fight against cancer," said Yale Provost Andrew Hamilton.
The new NFCR Center will work to develop a better understanding of how ▀-peptides can be designed to disrupt protein-protein interactions that transmit cell signals. When proteins behave abnormally, they often send incorrect signals that result in uncontrolled cell growth and division, and cancer. In their research, Schepartz and Jogensen will focus on developing new, more effective approaches to inhibit these abnormal protein-protein interactions and thereby block transmissison of cellular signals that lead to cancer growth.
Unlike the most commonly used small molecule inhibitors, ▀-peptides have a chemical structure very similar to that of their target proteins, allowing the drug to bind the target proteins more specifically and inhibit them more effectively. The Schepartz/Jorgensen team will use both cutting-edge experimental chemistry and elegant computer modeling to design and optimize ▀-peptide inhibitors of a wide range of targets. Since ▀-peptides are stable within the human body, their research has the potential to create a completely new technology platform for more effective and long-lasting anticancer drugs.
"This new center provides a vital link among the worldwide network of NFCR sponsored scientists that will significantly move our protein research to the forefront of cancer research," Schepartz said. "At Yale, we believe in the value of exploring every avenue in our quest to cure cancer, and with this partnership between NFCR and the university, we move one step closer to that goal."
The NFCR Center at Yale will collaborate with over 40 additional cancer researchers at universities and hospitals worldwide, and become a part of one of the largest cancer research networks in the world. Other NFCR Centers are at Oxford, Case Western Reserve, University of Alabama-Birmingham, University of California-Berkeley, Dana Farber Cancer Center, University of Arizona, Freie Universitńt Berlin, and the Institute of Medicinal Biotechnology in Beijing to form a broader international collaborative network of top researchers.
"The NFCR Center for Anti-Cancer Drug Design and Discovery at Yale University, will provide a new and vital link to the development of drug design that will undoubtedly lead to new, novel anticancer drugs that will help save lives," said Franklin Salisbury, Jr., President of the National Foundation for Cancer Research.
The Center was launched today at a mini-symposium in the new Class of '54 Chemical Research Building on Science Hill. In addition to Directors Schepartz and Jorgensen, speakers included NFCR President Franklin Salisbuty, Jr., and Yale Provost Andrew Hamilton.
Since it's founding in 1973, NFCR has spent more than $230 million funding basic science cancer research and cancer prevention education focused on understanding how and why cells become cancerous. NFCR is dedicated to funding scientists who are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the hope for curing cancer. For more information, visit www.NFCR.org or call 1-800-321-CURE (2873).
National Foundation for Cancer Research http://www.NFCR.org
Alanna Schepartz http://www.chem.yale.edu/faculty/schepartz.html
William Jorgenses http://www.chem.yale.edu/faculty/jorgensen.html
Andrew Hamilton http://www.yale.edu/provost/html/office.html
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.